New drug QLC5508 takes on chemo in prostate cancer battle

NCT ID NCT07632690

Not yet recruiting Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than docetaxel. Participants will receive either QLC5508 or docetaxel, and the study will track how long the cancer stays under control and overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QLC5508 (an experimental drug) and docetaxel (a standard chemotherapy)
What this could lead to: If QLC5508 works better than docetaxel, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: This is an early-stage Phase 3 trial, so results are not yet known. QLC5508 may not prove more effective or safer than docetaxel, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.